P W Grigsby1, L Hall-Daniels, S Baker, C A Perez. 1. Radiation Oncology Center, Mallinckrodt Institute of Radiology, St. Louis, Missouri 63110, USA. grigsbyp@netscape.net
Abstract
BACKGROUND: The purpose of this investigation was to evaluate the significance of race on the cancer-specific survival outcome of women treated with radiotherapy for advanced-stage cancer of the uterine cervix. METHODS: Data from 922 women with cancer of the uterine cervix treated with radiotherapy were reviewed. Patients were treated at the Mallinckrodt Institute of Radiology from 1959 through 1993. There were 576 women with clinical Stage II cancer and 346 women with clinical Stage III cancer. All women were treated following standard medical care treatment policies according to the stage of their disease. Data were analyzed by race and known treatment-related prognostic factors. Overall and cancer-specific survivals were evaluated. RESULTS: The 5-year cancer-specific survivals for clinical Stage II were 66 and 61% (P = 0.56) for white and black women, respectively. The corresponding 5-year overall survivals were 60 and 51% (P = 0.02). The 5-year cancer-specific survivals for clinical Stage III were 38 and 47% (P = 0.34) for white and black women, respectively. The associated 5-year overall survivals were 32 and 40% (P = 0.37). No differences in treatment-related factors were identified. CONCLUSIONS: In a cancer treatment system where black and white women with clinical Stage II and III cancer of the uterine cervix are all treated with radiotherapy alone, following standard treatment policies, no significant difference in cancer-specific survival outcome is shown. Multivariate analysis revealed that clinical stage and overall treatment time are significant variables affecting the control of tumor by radiotherapy. Overall survivals for the two racial groups are different and may be related to other non-cancer-related factors. Copyright 2000 Academic Press.
BACKGROUND: The purpose of this investigation was to evaluate the significance of race on the cancer-specific survival outcome of women treated with radiotherapy for advanced-stage cancer of the uterine cervix. METHODS: Data from 922 women with cancer of the uterine cervix treated with radiotherapy were reviewed. Patients were treated at the Mallinckrodt Institute of Radiology from 1959 through 1993. There were 576 women with clinical Stage II cancer and 346 women with clinical Stage III cancer. All women were treated following standard medical care treatment policies according to the stage of their disease. Data were analyzed by race and known treatment-related prognostic factors. Overall and cancer-specific survivals were evaluated. RESULTS: The 5-year cancer-specific survivals for clinical Stage II were 66 and 61% (P = 0.56) for white and black women, respectively. The corresponding 5-year overall survivals were 60 and 51% (P = 0.02). The 5-year cancer-specific survivals for clinical Stage III were 38 and 47% (P = 0.34) for white and black women, respectively. The associated 5-year overall survivals were 32 and 40% (P = 0.37). No differences in treatment-related factors were identified. CONCLUSIONS: In a cancer treatment system where black and white women with clinical Stage II and III cancer of the uterine cervix are all treated with radiotherapy alone, following standard treatment policies, no significant difference in cancer-specific survival outcome is shown. Multivariate analysis revealed that clinical stage and overall treatment time are significant variables affecting the control of tumor by radiotherapy. Overall survivals for the two racial groups are different and may be related to other non-cancer-related factors. Copyright 2000 Academic Press.
Authors: Sujana Movva; Anne-Michelle Noone; Mousumi Banerjee; Divya A Patel; Kendra Schwartz; Cecilia L Yee; Michael S Simon Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: Sarah C Markt; Tianyu Tang; Angel M Cronin; Ingrid T Katz; Brooke E Howitt; Neil S Horowitz; Larissa J Lee; Alexi A Wright Journal: PLoS One Date: 2018-02-15 Impact factor: 3.240
Authors: Mohammad A Tabatabai; Jean-Jacques Kengwoung-Keumo; Wayne M Eby; Sejong Bae; Juliette T Guemmegne; Upender Manne; Mona Fouad; Edward E Partridge; Karan P Singh Journal: PLoS One Date: 2014-09-16 Impact factor: 3.240
Authors: Janaka Weragoda; Andres Azuero; Suguna Badiga; Walter C Bell; Roland Matthews; Chandrika Piyathilake Journal: Cancer Med Date: 2016-05-17 Impact factor: 4.452